Importance of cost-effectiveness and value in cancer care and healthcare policy

J Surg Oncol. 2016 Sep;114(3):275-80. doi: 10.1002/jso.24331. Epub 2016 Jun 22.


The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280. © 2016 Wiley Periodicals, Inc.

Keywords: ICER; QALY; ductal carcinoma in-situ; prostate cancer; thyroid cancer; value.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / economics
  • Breast Neoplasms / therapy*
  • Cost-Benefit Analysis
  • Female
  • Health Policy*
  • Humans
  • Male
  • Outcome Assessment, Health Care
  • Prostatic Neoplasms / economics
  • Prostatic Neoplasms / therapy*
  • Quality-Adjusted Life Years
  • Thyroid Neoplasms / economics
  • Thyroid Neoplasms / therapy*